中商官网
研究报告
中国生物制药（HK1177）
| 科目\年度 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
原始货币 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 审计意见 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 报表核心指标 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 现金及现金等价物净增加额 |
-140909.20 | -124023.10 | -99205.40 | -37494.60 | -28703.10 | 430112.70 | 230052.00 | 40740.70 | 132825.60 | -43038.70 | 35655.50 | 34813.40 | 78269.49 |
| 经营活动现金流量净额 |
661512.00 | 606573.40 | 626515.50 | 536629.40 | 532533.60 | 532463.40 | 509436.40 | 373251.80 | 299486.50 | 229065.70 | 230019.20 | 157595.50 | 135763.00 |
| 投资活动现金流量净额 |
-170912.60 | -75697.49 | -407081.90 | -251597.70 | -784555.50 | -382434.40 | -61610.00 | -162704.60 | -223398.80 | -183348.10 | -278853.30 | -69212.90 | -4712.90 |
| 融资活动现金流量净额 |
-631508.60 | -654899.00 | -318639.00 | -322526.30 | 223318.80 | 280083.70 | -217774.40 | -169806.50 | 56737.90 | -88756.30 | 84489.60 | -53569.20 | -52780.60 |
| 现金及现金等价物期末余额 |
623152.30 | 750509.80 | 865480.50 | 959953.70 | 1062419.00 | 1063121.00 | 623502.90 | 369204.40 | 350243.50 | 253087.90 | 316723.00 | 289041.30 | 249473.30 |
| 经营活动现金流量净额 |
661512.00 | 606573.40 | 626515.50 | 536629.40 | 532533.60 | 532463.40 | 509436.40 | 373251.80 | 299486.50 | 229065.70 | 230019.20 | 157595.50 | 135763.00 |
| 折旧与摊销 |
132118.10 | 107428.40 | 104698.40 | 99255.60 | 165483.60 | 144561.10 | 117612.40 | 34338.90 | 31740.50 | 35331.00 | 25949.00 | 22394.30 | 17938.70 |
| 营运资金变动 |
9983.90 | -43051.40 | -19559.50 | -33913.50 | 26133.00 | -28281.10 | 24329.90 | 43067.90 | 32265.20 | -44533.80 | 2997.80 | -11527.60 | 14902.20 |
| 投资活动现金流量净额 |
-170912.60 | -75697.49 | -407081.90 | -251597.70 | -784555.50 | -382434.40 | -61610.00 | -162704.60 | -223398.80 | -183348.10 | -278853.30 | -69212.90 | -4712.90 |
| 资本性支出 |
139416.00 | 170370.90 | 170561.20 | 189398.40 | 185914.50 | 173396.30 | 169273.90 | 146018.00 | 89385.90 | 185714.60 | 63837.80 | 58272.39 | 34569.20 |
| 投资购买 |
-19546.10 | -9675.00 | -56422.90 | -247721.70 | -495643.60 | -174549.10 | -245221.10 | -117629.10 | -144495.00 | -267667.30 | -28281.60 | -8964.90 | -- |
| 融资活动现金流量净额 |
-631508.60 | -654899.00 | -318639.00 | -322526.30 | 223318.80 | 280083.70 | -217774.40 | -169806.50 | 56737.90 | -88756.30 | 84489.60 | -53569.20 | -52780.60 |
| 股份回购 |
-125220.00 | -39639.30 | -86761.30 | -33293.00 | -19537.30 | -3205.00 | -60441.90 | -- | -- | -- | -- | -- | -- |
| 支付股息 |
-221490.80 | -385450.80 | -296519.40 | -135139.60 | -271457.90 | -202085.90 | -175228.70 | -124725.40 | -96328.50 | -85371.20 | -75673.30 | -59133.50 | -47406.50 |
| 现金及现金等价物净增加额 |
-140909.20 | -124023.10 | -99205.40 | -37494.60 | -28703.10 | 430112.70 | 230052.00 | 40740.70 | 132825.60 | -43038.70 | 35655.50 | 34813.40 | 78269.49 |
| 加：现金及现金等价物期初余额 |
750509.80 | 865480.50 | 959953.70 | 1062419.00 | 1063121.00 | 623502.90 | 369204.40 | 350243.50 | 212108.50 | 316723.00 | 289041.30 | 249473.30 | 170581.60 |
| 汇率变动对现金及现金等价物的影响 |
13551.70 | 9052.40 | 4732.20 | -64971.10 | 28001.50 | 9505.40 | 24246.50 | -21779.80 | 5309.40 | -20596.40 | -7973.80 | 4754.60 | 622.20 |
| 现金及现金等价物期末余额 |
623152.30 | 750509.80 | 865480.50 | 959953.70 | 1062419.00 | 1063121.00 | 623502.90 | 369204.40 | 350243.50 | 253087.90 | 316723.00 | 289041.30 | 249473.30 |